Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that its first results from the ongoing inMMyCAR study, a Phase 1 clinical trial ...
YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...
Arcellx (ACLX) closed down ~17% Monday after privately held Kelonia Therapeutics released early-stage results from a small ...
Asianet Newsable on MSN
Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder
FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening ...
In vivo platform enables efficient, site-specific CAR gene insertion under control of an endogenous T cell promoter, producing functional CART ...
Xiangxue Life Sciences has agreed a strategic partnership with Guangzhou-based Damien Vaccines to co-develop in vivo TCR-T ...
Cell therapy’s next breakthrough could be the engineering of these cells inside the patient. Two deals more than four years apart put Astellas Pharma in position to ramp up its work developing these ...
Some of my most satisfying moments as a clinician over the past 50 years have been when I conducted in vivo behavior therapy exposure and practice with patients suffering from anxiety and phobias.
Rocket Pharmaceuticals (NASDAQ:RCKT) achieved its Nasdaq listing via a reverse merger with failing eye disease focused biotech Inotek back in 2017. The deal was completed and Rocket stock began to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback